Regulatory approval
Published by the Health Canada.
Health Canada approved imatinib mesylate for the treatment of adult patients with relapsed or refractory Ph+ALL as monotherapy.
This is written in the approval document as:
GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with relapsed or refractory Ph+ALL as monotherapy.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | BCR::ABL1 | Acute Lymphoid Leukemia | Imatinib |